Strategic alliance with National Cancer Centre Singapore to facilitate large scale clinical trials and commercialization of immunotherapy cancer treatments

The National Cancer Centre Singapore (NCCS) was established in 1999 to further enhance the country’s position as a preeminent center for cancer research, education and treatment in Asia Pacific. In July 2014, NCCS and Tessa Therapeutics entered into a research collaboration in the field of cellular therapy.

In June 2016, NCCS and Tessa Therapeutics expanded their research partnership with the formation of a broad strategic alliance. The alliance encompasses research, large-scale clinical trials and the development of world leading GMP manufacturing to facilitate the development, evaluation and commercialization of immune-oncology treatments for a wide range of cancers. NCCS has granted Tessa Therapeutics exclusive rights to license and commercialize all cancer immunotherapy products and technologies arising from NCCS’ immunotherapy research.  NCCS is also a strategic shareholder in Tessa Therapeutics.